---
document_datetime: 2025-06-27 12:24:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoonotic-influenza-vaccine-seqirus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zoonotic-influenza-vaccine-seqirus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.568599
conversion_datetime: 2025-12-15 06:50:19.799864
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Zoonotic Influenza Vaccine Seqirus

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 25/04/2025                          | 12/06/2025                                  | SmPC,                            | Please refer to Scientific Discussion Zoonotic |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249071                     | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of individuals 6 months of age and above for Zoonotic Influenza Vaccine Seqirus based on final results from study V87_30. This is a Phase 2, Randomised, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Paediatric Subjects 6 Months to < 9 Years of Age. As a consequence, sections 4.1, 4.2, 4.6, 4.7, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.1 of the RMP has been approved. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the PI. The requested variation proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk   |            |     | Labelling and PL   | Influenza Vaccine Seqirus Procedure No. EMA/VR/0000249071   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|-------------------------------------------------------------|
| Variation type IB / EMA/VR/0000248835 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/04/2025 | N/A |                    |                                                             |

<div style=\"page-break-after: always\"></div>

| B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|